**[미래에셋 제약/바이오 김승민]**
**10/21 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [GSK 만성 B형간염 치료제 Hibsago(bepirovirsen) FDA 승인](https://www.gsk.com/en-gb/media/press-releases/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-chronic-hepatitis-b-chb/) 

 [Astrazeneca, Oracle과 AI 기반 임상시험 파트너십 체결](https://news.google.com/rss/articles/CBMisAFBVV95cUxPWXlaZTY2Vmg3T3c4NVV4STEtUS05REdfNG5IU0tsczFpSHJpOHlWbExOU2dQQmxDSkdBOFh2aFVLMmdISEFjeVFYdXBOX0w0Z0ZRMVEyYTFkcC1ybTVUOVFwZElvT29kaS1DVlFBRVc4c21Yd0hFUEt5TlhpT1ZsTXA0OVpINmVsZ0lUZmt2bEw3ZnF0RFVYZUxKMExPNEJ3RDFodUhlXzROalNfOTAyRQ?oc=5)

 [Novo Nordisk의 CagriSema, 여성 대상 평균 25% 체중감량 달성 분석 결과](https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWk9PMTY1VkNlV0FHajFmSWJ5UVB4ZE83U1gyMTVlbjZLTG1QU01pUUlNR2dEUWVGQi1LbXE5UXl6dUszNFp2eTFfUnBoZkFEbW5kVGsxZXdLS3FkRUNWSVdTM0t5WkFFeVdwMHZ2eUJxc0lLYWJINVEwSmVNalJZUi1QN1VEQzNUcFZvY2pRemk0ZUhHQ0t5b0RkdXp5MkhxeE5GZ1hxcjJQdDdualA1MXNSVDdnWE9XS21j?oc=5)

 [신약 개발사 Lycia Therapeutics, 미국 IPO에서 $938M 기업가치 목표](https://news.google.com/rss/articles/CBMi2gFBVV95cUxQMnI3R0lXWnN4alVGb1k2Tm5fcDRNcDdmdnBCYlkzSVVnSmxmQ0VVXy1pVnU5V0c5Tmc4d0NKZXl3d1hvYmVwMXcwY0ZWcnVyNWlCN1RmZkRpaTJvdkJ1X2pQSWRBNVlkYlYyallTY3ZldkRqMi1yM19WN1ZyZVh5WERxdVA2ZFQwcVBkYmdDNmJuOFRwcHVMMzBtT0xSVVFrNjFxbTQteF9oYlFrcXBzamNranBGa2ZVdEpoeUVxa0NUYTkyeGFpTUN2NjNfQnVnbFVETlRtbmhNZw?oc=5)

 [Gilead, 궤양성 대장염 중기 임상 성공 발표 - IBD 주력 치료제 목표](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ibldYZ044ZUdQVU9TaHJOeW1HSU5jRk5CejBtOXdZZi1oY1lRcnpURUdBeXBMZzJhTTV1RzZGMDctWjJ3d0N4S3VfckIyOGZtR1VZ?oc=5)

 [Veradermics, 경구 탈모 치료제의 말기 임상시험에서 모발 성장 촉진 효과 입증](https://news.google.com/rss/articles/CBMi3AFBVV95cUxQUG9Sd25BdEpKc2wxMmRZYlEwSmlsd3QxRk51bEtZakZya2JITDlKWXIyb3RvR054YUxjSWRiMmJ6TnRnSk50dGFzQmZlUm90TzFHMTlPZjZYbnFERjZzXzM3ZE5hRFpmX1hEbDM0M1ltbXdKV2lGMnI4RjJ2NVg0MjdfaEQ4b01LOFlEcDhZV1pLTGU1eTdmNEZiejhpd0FHT2p5RGpxTkdEWmN2NnFhTjNWUkRtcG9MMFhaQjBxWkZQUDZjR1Y0UVhLdjFtaENiYU1TZlpqTzRTV05H?oc=5)


 **한국 바이오/제약**
────────────────────
 [삼성바이오 노조, 2차 총파업 잠정 연기…교섭 재추진](https://www.hitnews.co.kr/news/articleView.html?idxno=80052)

 [삼성바이오에피스, 브라질서 '솔리리스' 시밀러 10년 단독 공급](https://www.hitnews.co.kr/news/articleView.html?idxno=80032)

 [식약처, 원발성 담즙성 담관염 치료제 '리브델지' 허가](https://www.hitnews.co.kr/news/articleView.html?idxno=80050)

 [이오플로우, 인슐렛 소송전서 791억원 배상명령 받아](https://www.hitnews.co.kr/news/articleView.html?idxno=80053)

 [지놈앤컴퍼니, '릴리 튠랩' 참여해 AI 기반 신약개발 고도화](https://www.hitnews.co.kr/news/articleView.html?idxno=80040)

 ["세마글루티드, PCOS 환자 배란 주기 회복·임신율 향상 효과"](https://www.hitnews.co.kr/news/articleView.html?idxno=80037)

 [12개국 깔린 남미, 대웅 '나보타' 아르헨티나 공략 박차](https://www.hitnews.co.kr/news/articleView.html?idxno=80035)



────────────────────